Pharma Insights

Features

Pipeline Moves: Novartis resumes Phase II myelofibrosis trial, oncology trial completions

The Clinical Trials Arena team also investigates the completion of Phase II trials in liver and pulmonary diseases, Phase I/II in paediatric and Phase Ib/IIa colorectal cancer trials.

Clinical Trials Arena Team

//$tag = get_term_by('slug', 'featured', 'post_tag');

Features

Pipeline Moves: approval prospects jump for AstraZeneca’s breast cancer drug

//$tag = get_term_by('slug', 'featured', 'post_tag');

Features

Pipeline Moves: positive topline results in pulmonary hypertension, genetic and metabolic disorders

Features

Pipeline Moves: trial completions in glaucoma, lung, and oncology indications

Features

Pipeline Moves: trial terminations in colorectal cancer, cardiovascular infections, and kidney injury

Features

Pipeline Moves: Trial completions in Duchenne muscular dystrophy and chronic urticaria

Features

Pipeline Moves: Novartis completes Phase II Sjögren’s syndrome trial, advancement prospects jump

Features

Pipeline Moves: Sanofi terminates breast cancer trial, approval prospects plummet

Features

Pipeline Moves: Lilly completes pain, cancer trials, advancement prospects rise

Clinical Trials Arena Team

Features

Pipeline Moves: Lilly completes Phase II rheumatoid arthritis trial, next phase prospects rise

Clinical Trials Arena Team

Features

Pipeline Moves: Novartis Phase I/Ib cancer trial terminates, further study chances drop

Clinical Trials Arena Team

Features

Pipeline Moves: Phase II gout trial termination slashes advancement prospects

Clinical Trials Arena Team

Features

Pipeline Moves: Phase II essential tremor trial completes, advancement prospects jump

Clinical Trials Arena Team

Features

Pipeline Moves: Phase II head and neck cancer study terminated, advancement shot drops

Clinical Trials Arena Team

Features

Pipeline Moves: Novartis suspends platform trial, advancement shot of four blood cancer assets drop

Clinical Trials Arena Team

Features

Pipeline Moves: Nektar terminates Phase I/II cancer trial, further study shot in seven indications drop

Clinical Trials Arena Team

Features

Pipeline Moves: Further study shot dive for hepatitis B, pancreatic cancer assets after trials end early

Clinical Trials Arena Team

Features

Pipeline Moves: Further study shot of three cancer assets reviewed after early phase terminations

Clinical Trials Arena Team

Features

Pipeline Moves: Merck KGaA’s berzosertib progression shot in small-cell lung cancer reviewed after Phase II discontinued

Clinical Trials Arena Team

Features

Pipeline Moves: Eledon’s advancement shot in ALS reviewed after Phase IIa data reveal

Clinical Trials Arena Team

Features

Pipeline Moves: Myelodysplastic syndrome study on partial hold, solid tumour trial terminated

Clinical Trials Arena Team

Features

Pipeline Moves: Corcept’s Phase III pancreatic ductal adenocarcinoma trial termination leads to approval shot dive

Clinical Trials Arena Team

Features

Pipeline Moves: Premature Phase II end of cancer, acute pharyngitis clinical trials leads to advancement shot drop

Clinical Trials Arena Team

Features

Pipeline Moves: Boehringer, Stealth BioTherapeutics likely to see clinical trial progress of ophthalmic assets scuppered

Clinical Trials Arena Team

Features

Pipeline Moves: Pfizer terminates Phase II Braftovi, Mektovi trial, likely progress downturn in brain tumours

Clinical Trials Arena Team

Features

Pipeline Moves: Nektar’s approval shot in renal cell carcinoma, bladder cancer tumbles

Clinical Trials Arena Team

Features

AI benefits in patient identification and clinical trial recruitment has challenges in sight

Urtė Fultinavičiūtė

Features

Pipeline Moves: Phase II cancer trial of Roche asset terminated, shot at further study drops

Clinical Trials Arena Team

Features

Pipeline Moves: Terminations of fatty liver, blood cancer, ophthalmology clinical trials cause further study chances to nosedive

Clinical Trials Arena Team

Features

Alopecia areata steals the spotlight in time for possible treatment paradigm shift

Reynald Castañeda

News

NeuroSense previews Phase IIb trial plans for oral ALS drug

William Newton

Features

Pipeline Moves: Novartis ovarian cancer, fatty liver assets dive in further study chances after trial terminations

Clinical Trials Arena Team

Features

Covid-19 two years on: persistent symptoms of clinical trial disruption trouble certain therapy areas

Andrew Hillman

Features

Mapping Endpoints: Is the 6-minute walk test still the best Pompe disease clinical trial endpoint?

William Newton

Features

Pipeline Moves: Phase I/II cystic fibrosis trial of Horizon asset cancelled, shot at further study drops

Clinical Trials Arena Team

Ukraine Crisis

Clinical trials in Russia: big pharma makes moves but what’s the pipeline impact?

Reynald Castañeda

Features

The Opdualag effect: designing first-line melanoma clinical trials after anti-LAG-3 approval

Reynald Castañeda

Features

Pipeline Moves: Sorrento terminates Phase Ib CAR-T pancreatic cancer trial, shot at further study drops

Clinical Trials Arena Team

Subscribe to our Newsletter